ABBV · News · 20260930N
Product Pipeline Progress
AbbVie Inc. · 2026-09-30 · Importance 31 · Surprise 42 · In source text
AbbVie reported positive Phase 2 APEX Part B results for zumilokibart in adults with moderate-to-severe atopic dermatitis. All three dose regimens significantly improved EASI-75 response rates versus placebo at Week 16, and AbbVie selected the mid-dose regimen for Phase 3 development. The investigational IL-13 antibody also improved skin clearance and itch, with nasopharyngitis, headache and noninfective conjunctivitis among common adverse events. The results expand AbbVie’s dermatology pipeline ahead of potential future commercialization.
Key facts
- AbbVie selected the mid-dose regimen of zumilokibart for Phase 3 development. source
- In the Phase 2 APEX Part B study, all three zumilokibart dose regimens met the primary endpoint with significantly greater EASI-75 response rates versus placebo at Week 16. source
- Common adverse events observed with zumilokibart included nasopharyngitis, headache, and noninfective conjunctivitis. source
- Zumilokibart is a half-life extended monoclonal antibody targeting IL-13 in development for patients with atopic dermatitis. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | AbbVie selected the mid-dose regimen of zumilokibart for Phase 3 development. |
| operating_income | negative | probable | — | AbbVie selected the mid-dose regimen of zumilokibart for Phase 3 development. |